Trading Radar for 9/12: Manchester United (MANU), Applied Genetic Tech (AGTC), United Natural Foods (UNFI) Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
BMO Capital Reiterates Market Perform on United Natural Foods (UNFI) Following 4Q EPS Beat
September 13, 2016 9:10 AM EDTBMO Capital reiterated a Market Perform rating and $45.00 price target on United Natural Foods (NASDAQ: UNFI) following the company's 4Q earnings report. UNFI reported adjusted EPS of $0.70 compared with the consensus of $0.63.
Analyst Kelly Bania commented, "UNFI reported better-than-expected adjusted FY4Q16 EPS of $0.70... More
BMO Capital Cuts Price Target on Applied Genetic Technologies (AGTC) to $20
September 13, 2016 8:18 AM EDTBMO Capital maintained an Outperform rating on Applied Genetic Technologies Corp. (NASDAQ: AGTC), and cut the price target to $20.00 (from $25.00), after updating estimates. BMO is now expecting data for XLRS in 2017 vs 2H16 previously as enrollment is slower-than-expected. The trial has enrolled 8/27 patients... More
